Osiris Therapeutics Inc (OSIR.OQ)
6 Dec 2016
Fri, Oct 14 2016
BRIEF-Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial
* says on October 14, 2016, company commenced steps to terminate enrollment in its OTI-15-01 phase III clinical trial
* Says continuing to work to complete its previously announced accounting reviews, restatements of prior period financial statements
* Says is in process of completing accounting review of revenue recognition under contracts with distributors
- Osiris Therapeutics: Regenerative Technologies And Restated Financials
- Is It Time To Invest In Stem Cell Biotechs?
- Osiris Therapeutics Beset By Newer And Bigger Troubles
- Microsoft's Big New Move In Mobile Ads
- Osiris: Aggressive Channel Stuffing, Accounting Irregularities Or Outright Fraud?
- The Resignation Of Osiris Therapeutics' Auditor Really Opens The Door For More Accounting Concerns